RPL32

Across TCGA pan-cancer cohorts, RPL32 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RPL32 data layer compared with 25 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher RPL32 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated RPL32 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

CCRCC, LUAD, and GBM are the cancer types where RPL32 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	IV	0.123	0.785	.009	13	view →
LUAD	DFS	Quartile	III,IV	0.862	0.237	.015	9	view →
GBM	DFS	Tertile	All	0.275	0.489	.017	8	view →
OV	DFS	Median	All	0.611	1.000	.005	4	view →
LSCC	OS	Median	All	1.000	0.939	.013	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RPL32–CCRCC (OS)

Open the CCRCC breakdown →